These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33789884)

  • 41. Test and treat: a missing link in the global fight against COVID-19.
    Wroe EB; Seung KJ; Baker BK; Farmer PE
    Lancet Glob Health; 2022 Feb; 10(2):e181-e182. PubMed ID: 34953515
    [No Abstract]   [Full Text] [Related]  

  • 42. Toxic epidermal necrolysis after ivermectin.
    Seegobin K; Bueno E; Maharaj S; Ashby T; Brown M; Jones L
    Am J Emerg Med; 2018 May; 36(5):887-889. PubMed ID: 28927997
    [No Abstract]   [Full Text] [Related]  

  • 43. An update of anti-viral treatment of COVID-19.
    Şimşek-Yavuz S; Komsuoğlu Çelikyurt FI
    Turk J Med Sci; 2021 Dec; 51(SI-1):3372-3390. PubMed ID: 34391321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An EUA for sotrovimab for treatment of COVID-19.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
    [No Abstract]   [Full Text] [Related]  

  • 46. The WHO's chief scientist on a year of loss and learning.
    Swaminathan S
    Nature; 2020 Dec; 588(7839):583-585. PubMed ID: 33335314
    [No Abstract]   [Full Text] [Related]  

  • 47.
    Brown RE; Tahseen D
    Ann Clin Lab Sci; 2020 Nov; 50(6):837-841. PubMed ID: 33334802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What are the mechanisms associated with post-ivermectin serious adverse events?
    Boussinesq M; Kamgno J; Pion SD; Gardon J
    Trends Parasitol; 2006 Jun; 22(6):244-6. PubMed ID: 16632406
    [No Abstract]   [Full Text] [Related]  

  • 49. Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever.
    Watson C
    Nat Med; 2022 Jan; 28(1):2-5. PubMed ID: 35031791
    [No Abstract]   [Full Text] [Related]  

  • 50. COVID-19: Panama stockpiles unproven drugs.
    Torres-Atencio I; Goodridge A; Vega S
    Nature; 2020 Nov; 587(7835):548. PubMed ID: 33235365
    [No Abstract]   [Full Text] [Related]  

  • 51. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 52. [Drug-induced eruption after treatment of hyperkeratotic crusted scabies with ivermectin].
    Mara C; Sarrot-Reynauld F; Mallaret M; Raclot-Roy N; Massot C
    Rev Med Interne; 2004 Jun; 25(6):476-7. PubMed ID: 15158324
    [No Abstract]   [Full Text] [Related]  

  • 53. The role of chemical biology in the fight against SARS-CoV-2.
    Burslem GM
    Biochem J; 2021 Jan; 478(1):157-177. PubMed ID: 33439990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutaneous lesions and COVID-19: Cystic painful lesion in a case with positive SARS-CoV-2.
    Goudarzi S; Dehghani Firouzabadi F; Dehghani Firouzabadi M; Rezaei N
    Dermatol Ther; 2020 Nov; 33(6):e14266. PubMed ID: 32882081
    [No Abstract]   [Full Text] [Related]  

  • 55. Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis.
    Shimizu K; Hirata H; Kabata D; Tokuhira N; Koide M; Ueda A; Tachino J; Shintani A; Uchiyama A; Fujino Y; Ogura H
    J Infect Chemother; 2022 Apr; 28(4):548-553. PubMed ID: 35016823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
    DiNicolantonio JJ; Barroso J; McCarty M
    Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mazzotti reaction with eosinophilia after undergoing oral ivermectin for scabies.
    Ito T
    J Dermatol; 2013 Sep; 40(9):776-7. PubMed ID: 23855317
    [No Abstract]   [Full Text] [Related]  

  • 59. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.
    Zhang R; Tang Y
    Viral Immunol; 2021 Jun; 34(5):291-299. PubMed ID: 32614684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 Laboratory Testing/CDC Guidelines.
    McFee DRB
    Dis Mon; 2020 Sep; 66(9):101067. PubMed ID: 32883517
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.